Related Experiment Video
Updated: Apr 10, 2026

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
Published on: October 17, 2013
Polymeric Drug-Delivery Systems: Role in P-gp Efflux System Inhibition
Preeti Gupta1, Tarun Garg2, M Tanmay1
1Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.
Abstract:
Permeability glycoprotein (P-gp), a multispecific drug transporter belonging to the multidrug resistance (MDR) gene subfamily, is mainly responsible for efflux of diffused intracellular drugs, resulting in poor drug bioavailability. P-gp is overexpressed in the blood-brain barrier, gastrointestinal tract (GIT), kidney, liver, pancreas, and cancerous cells, leading to multidrug resistance and failure of therapy. Because P-gp is transported into cells by way of receptor-mediated endocytosis (in contrast to diffusion for free drug), polymeric efflux pump modulators can have a major role in efficient drug delivery. Various polymer drug conjugates that have been proven to provide potential treatments in MDR cases are reviewed here, with an emphasis on the role of the P-gp efflux pump, bioavailability, and the mechanism of inhibition of the P-gp transporter by various polymers and delivery systems. This review also highlights the potential of specific polymer drug conjugates to act as P-gp efflux pump inhibitors to provide enhanced bioavailability and therapeutic efficacy.
Related Concept Videos
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Modified-Release Drug Delivery Systems: Influencing Factors
Oral Drug Delivery Systems: Continuous-Release Systems
Oral Drug Delivery Systems: Delayed-Release Systems

